Press Releases

Circassia Raises £11 million ($21.8 million) In Oversubscribed Second Round Funding

OXFORD, UK – 29 January 2008 – Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced today that it has successfully raised £11 million ($21.8 million) in an oversubscribed second round...

View details

Circassia Completes In-Licensing of Anti-Allergy Intellectual Property Portfolio

OXFORD, UK – 29 November 2007 – Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced the in-licensing of anti-allergy intellectual property from Monash University in Australia and the Vienna-based...

View details

Circassia Initiates Clinical Blood Sample Trial With Organ Anti-Rejection Technology

OXFORD, UK – 29 September 2007 – Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced the initiation of a clinical blood sample testing programme with it’s organ anti-rejection technology...

View details

Circassia Announces Acquisition of Organ Transplant Anti-Rejection Technology

Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced the acquisition of a novel anti-rejection technology for use in organ transplantation. Circassia acquired the proprietary technology, known as ToleroTrans, from...

View details

Circassia Announces the Appointment of Sir Richard Sykes as Chairman of the Board

Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced the appointment of Sir Richard Sykes as Chairman of the Board. Sir Richard succeeds Charles Swingland who held the post of...

View details

Circassia Announces the Appointment of Paul Laidler as Director of Pharmaceutical Sciences

Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced the appointment of Dr Paul Laidler as Director of Pharmaceutical Sciences. “We are delighted that Paul is joining the team at...

View details

Circassia Announces the Appointment of Rod Hafner as Vice President, Research and Development

Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced the appointment of experienced industry scientist Dr Rod Hafner as Vice President, Research and Development. “We are delighted that Rod is...

View details

Circassia Completes Multi-million Pound Fund Raising

Circassia today announced that it has completed a substantial multi-million pound fund raising to further develop its allergy vaccine techology. The funding round, which included Landsdowne Partners and Tudor Capital was led by Imperial Innovations....

View details